Twist1 is an essential transcription factor required to initiate epithelial-mesenchymal transition (EMT) and promote tumor metastasis. PAQR3 is a newly found tumor suppressor that is frequently downregulated in many types of human cancers. Downregulation of PAQR3 is associated with accelerated metastasis and poor prognosis of the patients with gastric cancers. In this study, we demonstrate that PAQR3 is actively involved in the degradation of Twist1 and whereby regulates EMT and metastasis of gastric cancer cells. PAQR3 overexpression reduces the protein level but not the mRNA level of Twist1. The protein stability and polyubiquitination of Twist1 are altered by PAQR3. PAQR3 forms a complex with Twist1 and BTRC, an E3 ubiquitin ligase. PAQR3 enhances the interaction between Twist1 and BTRC. Twist1 is mobilized from the nucleus to a proteasome-containing structure in the cytoplasm upon overexpression of PAQR3 and BTRC, which is required for PAQR3induced degradation of Twist1. The Twist1 box domain of the Twist1 protein is required for the interaction of Twist1 with both PAQR3 and BTRC, indispensable for PAQR3-mediated degradation of Twist1. Both BTRC and Twist1 are required for the inhibitory effects of PAQR3 on migration and EMT phenotype of gastric cancers cells. Importantly, Twist1 is indispensable for the inhibitory effect of PAQR3 on metastasis of gastric cancer cells in vivo. Collectively, these findings not only pinpoint that Twist1 mediates the modulatory function of PAQR3 on EMT and metastasis but also suggest that targeting Twist1 is a promising strategy to control metastasis of tumors with downregulation of PAQR3.
Introduction
Epithelial-mesenchymal transition (EMT) is a critical process that allows epithelial cells to lose their junctions and apicalbasal polarity, leading to gain the mobility and invasive phenotype of the cancer cells (1, 2) . The EMT program is initiated by a set of key transcription factors such as Twist1, Snail and ZEB (1) . These transcription factors execute EMT by repressing genes encoding epithelial-like proteins and activating mesenchymal genes (3, 4) . Twist1 is a basic helix-loop-helix domain-containing transcription factor. Functional loss of Twist1 was found to cause several diseases such as Saethre-Chotzen syndrome (5) . Twist1-null mouse embryos die from defective development in head mesenchyme, somites and limb buds (6) . Twist1 has a very broad impact on the metastatic processes of tumor cells, as it is essential for cell-cell adhesion via suppression of epithelial marker such as E-cadherin and catenin as well as augmentation of mesenchymal markers such as vimentin and N-cadherin (7, 8) . The protein level of Twist1 is affected by multiple signaling pathways. HIF-1α could directly regulate Twist1 expression (9) . MAPKs phosphorylate Twits1 at Ser68 to block ubiquitin-mediated degradation of the protein (10) . It was also reported that BTRC (also known as β-Trcp or FBXW1) is the E3 ubiquitin ligase of Twist1 and involved in the degradation and the protein (11) .
Recent studies have indicated that Twist1 is associated with the invasive and metastatic phenotypes of many tumor types (8, 12) . Twist1 was reported to be associated with the initiation, progression and metastasis of gastric cancer (13, 14) , breast cancer (8) , hepatocellular carcinoma (15) , prostate cancer (16) , esophageal squamous cell carcinoma (17) , bladder cancer (18) and pancreatic cancer (19) . Our study revealed that Twist1 is likely involved in the progression and metastasis of human gastric cancers via functional interaction with PAQR3 (20) . PAQR3, also named as RKTG for Raf kinase trapping to Golgi, belongs to the PAQR (progesterone and adipoQ receptor) superfamily (21) . It is a membrane protein specifically localized in the Golgi apparatus with seven trans-membrane motifs (22) . PAQR3 was originally characterized as a spatial regulator of Raf kinase (23) . PAQR3 binds Raf kinase and sequesters it to the Golgi apparatus and consequently represses Ras/MAPK signaling (23) . PAQR3 functions as a tumor suppressor mainly due to its inhibitory activity on Raf/MAPK and PI3K/AKT signaling pathways (23) (24) (25) (26) (27) . We recently found that PAQR3 was frequently downregulated in human gastric cancer samples (20) . The expression level of PAQR3 was negatively correlated with tumor size, tumor stage, venous and lymphatic invasion, distant and nodal metastasis, and the survival duration of gastric cancer patients (20) . In addition, downregulation of PAQR3 was highly correlated with increased expression of Twist1 in gastric cancer samples (20) . These findings led us to hypothesize that PAQR3 is likely involved in the regulation of Twist1. As reported in this study, we demonstrate for the first time that PAQR3 plays a vital role in regulating protein stability and degradation of Twist1 and whereby modulates metastasis of gastric cancer cells.
Materials and Methods

Cell culture
The human embryonic kidney cells (HEK293T) and human cervix adenocarcinoma HeLa cells were maintained in Dulbecco's modified Eagle's medium. The human gastric adenocarcinoma AGS, SNU-16, BGC-823 and NCI-N87 cells were cultured with F12K or RPMI 1640 medium. All the cell culture media were added with 10% fetal bovine serum, and the cells were cultured at 37°C with 5% CO 2 in humidified atmosphere. The authentication of all cell lines used has been confirmed.
Plasmids
Full-length coding Twist1 and BTRC were cloned by RT-PCR from human cells and confirmed by sequencing. The primers for cloning full-length Twist1 and BTRC were as follows: 5′-ATGATGCAGGACGTGTCCAG-3′ and 5′-ACAATGACATCTAGGTCTCC-3′ for Twist1; 5′-ATGGACCCGGCCGAGGCGGTG-3′ and 5′-TTATCTGGAGA TGTAGGTGTATG-3′ for BTRC. Several expression constructs of Twist1, PAQR3 and BTRC were generated using standard molecular techniques. The PAQR3-specific shRNA (short hairpin RNA) construct was established before as reported (28) . The BTRC-and Twist1-specific shRNA was purchased from Genechem Bio Ltd (Shanghai, China) with following sequences: 5′-TTCTCCGAACGTGTCACGT-3′ for the scrambled control, 5′-ATTAAAGTTGCGGTATTTA-3′ for BTRC and 5′-TGAGCAACAGCGAGGAAGA-3′ for Twist1. All deletion mutations of Twist1 were generated by PCR followed by fusion to a pEGFP-C1 vector. The knockdown of PAQR3, BTRC and Twist1 was performed by a lentivirus-based method. AGS cells with stable expression of luciferase were infected with different shRNA-containing lentivirus.
Lentivirus production and infection
The knockdown of PAQR3, BTRC and Twist1 was performed by a lentivirusbased method. AGS cells with stable expression of luciferase were infected with different shRNA-containing lentivirus. The lentiviral vector of FG12-PAQR3-shRNA has an independent open reading frame from that of green fluorescent protein. BTRC-shRNA and Twist1-shRNA vectors have an independent open reading frame from that of puromycin. These vectors were transfected into HEK293T cell and the virus was harvested from the supernatant after transfection for 48 and 72 h. The lentivirus was purified by centrifugation at 20 000 rpm (4°C, 120 min). Appropriate amounts of the lentivirus were added into the culture medium of AGS cells. At 72 h after the infection, the cells were sorted by flow cytometry (BD Biosciences, San Diego, CA) or selected for puromycin resistance.
Extraction of cytoplasmic proteins
A cytoplasmic protein extraction kit was purchased from Sangon Biotech Ltd (Shanghai, China). The cells were washed with ice-cold phosphatebuffered saline (PBS) at 24 h after the transfection and then harvested by scrapping with 1 ml PBS before extraction of cytoplasmic proteins according to the instruction of the manufacturer.
Co-immunoprecipitation and western blotting
Co-immunoprecipitation (co-IP), western blotting, immunofluorescence and confocal studies were performed using methods as reported previously (23, 27) . The antibodies against following proteins were as follows: Flag from Sigma-Aldrich (St Louis, MO); green fluorescent protein and β-actin from Santa Cruz (Santa Cruz, CA); His from Transgen (Shanghai, China); proteasome 20S alpha+beta, E-cadherin, N-cadherin, Twist1 and vimentin from Abcam (Cambridge, MA); BTRC from Abgent (San Diego, CA).
Immunofluorescence studies
HeLa and SNU-16 cells were cultured in glass slides and were transfected with different plasmids. At 24 h post-transfection, the cells were treated with or without MG132 (10 µM) for 6 h. The cells were then fixed with 4% paraformaldehyde, permeabilized by 0.1% Triton X-100 in PBS for 10 min. The cells were blocked in 3% bovine serum albumin in PBS at 4°C overnight and then incubated with the antibodies against Flag tag (Sigma-Aldrich), HA tag (Santa Cruz), GM130 (Abcam), proteasome 20S alpha+beta (Abcam), followed by incubation with secondary antibodies including Alexa Fluor 488 goat anti-mouse IgG (Abcam), Alexa Fluor 488 goat antirabbit IgG (Abcam), Alexa Fluor 546 goat anti-mouse IgG (Abcam), Alexa Fluor 546 goat anti-rabbit IgG (Abcam), Alexa Fluor 633 goat anti-mouse IgG (Abcam), or Alexa Fluor 633 goat anti-rabbit IgG (Abcam). Fluorescence images were acquired with a Nikon microscope (E600).
Two-step co-IP
HEK293T cells were cotransfected with Myc-tagged PAQR3, Flag-tagged BTRC and His-tagged Twist1. For the control of first IP, the HA-tagged Twist1 was used. The cells were harvested at 36 h after the transfection and lysed with IP lysis buffer, sonicated and centrifuged. The supernatant was incubated with an anti-His antibody bound to protein A/G-agarose beads for 2 h at 4°C. The beads were then washed with lysis buffer (containing 150 mM NaCl) three times, and the PAQR3 protein complex was eluted with 300 µl of lysis buffer (containing 250 mM NaCl and His peptide) for 2-3 h at 4°C. The second IP was performed using 150 µl of the eluate from the first IP and 350 µl of lysis buffer containing 464 mM NaCl and an anti-Myc antibody (Santa Cruz) or control IgG (Santa Cruz), followed by the addition of protein G-agarose beads.
Glutathione-S-transferase pull-down assay
The pGEX-4T-1 vector containing glutathione-S-transferase (GST)-fused N-terminal 1-71 amino acid [PAQR3 (1-71)], pET-28a(+)-BTRC and pET-28a(+)-Twist1 plasmids were transformed into BL21 bacteria. After the BL21 transformants were inoculated in 5 ml of Lysogeny broth medium overnight. About 100 mM of isopropyl-thio-β-d-galactoside was added into the medium and then cultured for 12 h at 18°C. The bacteria were broken Abbreviations co-IP co-immunoprecipitation EMT epithelial-mesenchymal transition GST glutathione-S-transferase PBS phosphate-buffered saline by six to nine rounds of sonication. After centrifugation, the supernatant was transferred into a fresh tube and then added with NETN buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 0.5% NP40, 1 mM ethylenediaminetetraacetic acid) 1 ml of prewashed GST-sepharose beads (GE) or Ni-NTA agarose beads (Qiagen). The beads were washed with NETN buffer five times, and equal volume of NETN buffer was used to dissolve the beads. A portion of the beads (20 µl) was mixed with 5 µl 5× sodium dodecyl sulfate loading buffer, boiled for 6 min before loading into sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel.
In vitro migration and metastasis assays
In vitro migration assay was performed as described previously (20) . In transwell assay, 3 × 10 4 cells were seeded into each chamber and the migration of the cells were detected in 24 h. The AGS cells with stable expression of luciferase were established with puromycin selection. The luciferase expression was analyzed using luciferin and determined by an in vivo imaging system (Xenogen, Alameda, CA). In brief, 1 × 10 6 cells were suspended in 100 µl PBS and injected through vein tail of the nude mice. The metastatic foci of the lungs were detected in the first, third and sixth week following the injection. At 6 weeks after the injection, the mice were killed and the lungs were used in hematoxylin and eosin staining. All animals were maintained and used in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Institute for Nutritional Sciences.
All of the experimental procedures were carried out in accordance with the CAS ethics commission with an approval number 2010-AN-8.
Statistical analysis
The statistical comparisons were performed using independent Student's t-test. These data are shown as mean ± SD, and the significance was set at a P value of <0.05. The statistical significance of differences between groups was assessed using GraphPad Prism 5.0 software.
Results
PAQR3 regulates degradation of Twist1 protein
We have reported previously that PAQR3 downregulation is associated with upregulation of Twist1 in human gastric cancer (20) .
To identify whether PAQR3 could regulate Twist1, we expressed different amounts of PAQR3 in a gastric cancer cell line AGS. Interestingly, the Twist1 protein level was decreased by PAQR3 overexpression in a dose-dependent manner in AGS cells ( Figure 1A ). We next investigated whether such negative regulation on Twist1 by PAQR3 occurred at the transcriptional level. We found that the mRNA level of Twist1 was not altered by PAQR3 overexpression ( Figure 1B) , indicating that PAQR3 impacted on Twist1 expression post-transcriptionally. We next analyzed the protein degradation rate of Twist1 in the presence of cycloheximide. In AGS cells with stable expression of PAQR3, the degradation kinetics of Twist1 protein was markedly enhanced by PAQR3 overexpression ( Figure 1C ). In contrast, the degradation rate of Twist1 was profoundly delayed when endogenous PAQR3 was silenced by a PAQR3-specific shRNA ( Figure 1D ). These findings therefore suggested that the protein stability of Twist1 is reduced by PAQR3.
To further investigate whether the altered Twist1 stability by PAQR3 occurred via the ubiquitin-mediated proteasome degradation, we analyzed the ubiquitination level of endogenous Twist1 in the presence or absence of MG132, a proteasome inhibitor. We found a significant increase in the polyubiquitination level of Twist1 upon PAQR3 overexpression in AGS cells ( Figure 1E ). Collectively, these data indicated that PAQR3 is implicated in ubiquitin-mediated degradation of Twist1 protein in gastric cancer cells.
PAQR3 enhances the interaction of Twist1 and BTRC
A previous study has reported that BTRC was a candidate of the E3 ubiquitin ligase of Twist1 (11) . We therefore postulated that PAQR3 was likely involved in the interaction of Twist1 with BTRC. We used co-IP assays to investigate the protein interactions among Twist1, BTRC and PAQR3 in HEK293 cells that were chosen due to the high efficiency of plasmid transfection. As expected, Twist1 was able to interact with BTRC ( Figure 2A ). Intriguingly, BTRC was able to interact with PAQR3 ( Figure 2B ). On the other hand, PAQR3 also had an interaction with Twist1 ( Figure 2C ). We next performed a two-step IP assay and found that PAQR3, BTRC and Twist1 could form a complex simultaneously ( Figure 2D ). Consistently, ectopically expressed PAQR3 could interact with endogenous BTRC and endogenous Twist1 by a co-IP assay ( Figure 2E ). We next analyzed whether PAQR3 directly interacted with Twist1 and BTRC. We constructed a GST fusion protein that contained the N-terminal 1-71 amino acid of PAQR3 and this region is facing cytosol (22) . Previous studies also indicated this region mediates the interaction of PAQR3 with other proteins (27, 29) . We found that GST-PAQR3(1-71) could only pull-down BTRC, but not Twist1 ( Figure 2F ), suggesting that PAQR3 directly interact with BTRC but not Twist1.
As PAQR3 overexpression could induce degradation of Twist1 (Figure 1 ), we suspected that PAQR3 might enhance the interaction of Twist1 and BTRC to accelerate the degradation of Twist1. We found that overexpression of PAQR3 could indeed promote the interaction of Twist1 with BTRC in the cytoplasm in a dosedependent manner ( Figure 2G ). Therefore, our data suggested that PAQR3 forms a protein complex with Twist1 and BTRC and enhances Twist1 degradation by facilitating binding of Twist1 with its E3 ubiquitin ligase BTRC.
Twist1 is mobilized to the proteasome-containing structure by PAQR3 and BTRC
As reported previously, PAQR3 protein is specifically localized in the Golgi apparatus (22, 23) . We next investigated whether the subcellular localization of BTRC and Twist was changed by PAQR3. As expected, PAQR3 alone was completely localized in the Golgi apparatus, shown as clear colocalization with a Golgi marker GM130 ( Figure 3A) . Both BTRC and Twist1, when expressed alone, were mainly localized in the nucleus ( Figure 3A) , consistent with previous reports (30, 31) . Upon MG132 treatment, PAQR3 was distributed in punctiform structures with a loss of colocalization with the Golgi marker ( Figure 3B ), whereas BTRC and Twist1 were still mainly in the nucleus ( Figure 3B ). Intriguingly, coexpression of PAQR3 and BTRC robustly altered the subcellular localization of BTRC with most BTRC being mobilized to the Golgi apparatus ( Figure 3C ). Likely, BTRC was also well colocalized with PAQR3 in the presence of MG132 ( Figure 3D ). However, PAQR3 could not change nuclear localization of Twist1 ( Figure 3E and F). Although both BTRC and Twist1 were colocalized in the nucleus ( Figure 3G ), MG132 treatment led to colocalization of BTRC with Twist1 in punctiform structures in the cytoplasm together with their nuclear compartmentalization ( Figure 3H ). When PAQR3, BTRC and Twist1 were coexpressed, all three proteins were colocalized in the cytoplasm in the presence of MG132 ( Figure 3I and Supplementary Figure S2A , available at Carcinogenesis Online). Furthermore, Twist1 and BTRC had an apparent colocalization with a proteasome marker proteasome 20S in the presence of PAQR3 coexpression upon MG132 treatment ( Figure 3J and Supplementary Figure S2A , available at Carcinogenesis Online). Collectively, these results suggested that the nuclear Twist1 can be mobilized to a proteasome-containing structure by coexpression of PAQR3 and BTRC. Such conclusion was further supported by the colocalization studies using gastric cancer cells ( Supplementary Figures S1 and S2B , available at Carcinogenesis Online).
PAQR3-induced Twist1 degradation is dependent on BTRC
Within the hypothetical PAQR3/Twist1/BTRC complex, it would be expected that BTRC is crucial for Twist1 degradation due to its E3 ubiquitin ligase activity. We found that BTRC could also enhance the interaction of PAQR3 with Twist1 in the cytoplasm ( Figure 4A ). Knockdown of endogenous BTRC could notably block PAQR3 binding with Twist1 ( Figure 4B ). Overexpression of BTRC alone did not reduce the level of Twist1 protein in AGS cells ( Figure 4C ). However, overexpression of BTRC with PAQR3 robustly decreased the protein level of Twist1 ( Figure 4C ). To further analyze the importance of PAQR3 and BTRC on Twist1 degradation, we analyzed ubiquitination of Twist1 in the presence of PAQR3 overexpression and BTRC downregulation. Similar to our previous observation ( Figure 1E ), PAQR3 overexpression enhanced polyubiquitination of Twist1 ( Figure 4D ). However, the PAQR3-mediated ubiquitination of Twist1 was completely abolished by BTRC downregulation. Therefore, these results indicated that both PAQR3 and BTRC are essential for Twist1 degradation, consistent with the immunofluorescence results ( Figure 3 ). Based on our results, we postulated that PAQR3 facilitates the complex formation of BTRC with Twist1, whereby enhancing ubiquitination of Twist1 by BTRC ( Figure 4E ). However, we cannot rule out the possibility that the interaction of Twist1 with PAQR3 can be facilitated by another unknown protein/molecule ( Figure 4E ).
PAQR3-induced Twist1 degradation is depended on the Twist1 box domain of Twist1
According to a previous report (32) , Twist1 has four function domains including Twist1 domain (1-46aa), glycine-rich region domain (47-102aa), bHLH domain (113-168aa) and Twist1 box domain (169-202aa) ( Figure 5A ). We established different deletion domain of Twist1, including Twist1 (Δ1-46), Twist1 (Δ47-102), Twist1 (Δ113-168) and Twist1 (Δ169-202) to remove these functional domains. By co-IP assays, we found that the Twist1 box is required for the interaction of Twist1 with both PAQR3 and BTRC, as deletion of this domain led to a complete loss of the interaction of Twist1 with the two other proteins ( Figure 5B and C). We suspected that Twist1 box domain (169-202aa) was vital to PAQR3-induced Twist1 degradation, so we examined the ubiquitination level of Twist1 and its mutant Twist1(Δ169-202) in PAQR3-overexpressed cells. Consistently, the PAQR3-induced polyubiquitination of Twist1 was completely lost when the Twist1 box domain was deleted ( Figure 5D ). Likewise, PAQR3-accelerated decay of Twist1 protein was abrogated by deletion of the Twist1 box domain in both HEK293T and AGS cells ( Figure 5E and F) . These data, therefore, indicated that the Twist1 box domain is critical for the interaction of Twist1 with PAQR3 and this domain is indispensable for PAQR3-mediated polyubiquitination and degradation of Twist1 protein. 
Both BTRC and Twist1 are essential for PAQR3inhibited EMT and metastasis in gastric cancer
As our recent study has revealed that PAQR3 is involved in the progression and metastasis of human gastric cancers (20) , we next explored the functional roles of BTRC and Twist1 in PAQR3mediated inhibition of migration and metastasis of gastric cancer cells. As expected, PAQR3 overexpression significantly decreased the migration of AGS cells derived from human gastric cancer ( Figure 6A ). However, downregulation of endogenous BTRC by a BTRC-specific shRNA significantly abrogated the inhibitory effect of PAQR3 on AGS cell migration ( Figure 6A ). PAQR3 overexpression in AGS cells reduced Twist1 protein level, whereas increased an epithelial marker E-cadherin and reduced mesenchymal markers N-cadherin and vimentin ( Figure 6B) . The PAQR3mediated alterations of Twist1 and EMT markers were abrogated by BTRC silencing (Figure 6B ). On the other hand, knockdown of endogenous PAQR3 strongly promoted cell migration in AGS cells, but such promoting effect of PAQR3 was almost completely abrogated by simultaneous knockdown of Twist1 ( Figure 6C) . Consistently, the alteration of EMT markers upon PAQR3 silencing was abrogated by Twist1 knockdown (Figure 6D ). These results, therefore, indicated that the regulatory effects of PAQR3 on migration and EMT of gastric cancer cells are dependent on Twist1 and BTRC. The importance of PAQR3 on the migration of tumor cells was further strengthened by analyzing the inverse correlation of PAQR3 expression level with migration activity in a panel of gastric cancer cells (Supplementary Figure S3 , available at Carcinogenesis Online). In addition, compared with the robust effects on cell migration by PAQR3, BTRC and Twist1 ( Figures 6A  and C and Supplementary Figure S4 , available at Carcinogenesis Online), these molecules only had slight effects on cell proliferation ( Supplementary Figure S5 , available at Carcinogenesis Online), indicating that they mainly impact migration instead of proliferation in the gastric cancer cells. We next investigated that the function of Twist1 in PAQR3inhibited metastasis of gastric cancer cells. We established a luciferase-labeled AGS cell line with knockdown of PAQR3 and/ or Twist1 was injected into nude mice via tail vein. Compared with the controls, knockdown of PAQR3 profoundly enhanced tumor metastasis, shown as a significant increase in the intensity of luciferase activity ( Figure 6E ) and formation of metastasized tumors in the lung ( Figure 6F ). However, knockdown of Twist1 robustly abrogated the metastasis-promoting effect of PAQR3 downregulation ( Figure 6E and F) . Collectively, these data indicate that the metastasis-promoting effect of PAQR3 downregulation in gastric cancer cells is dependent on Twist1. These results, therefore, are consistent with the clinical findings that PAQR3 downregulation is associated with upregulation of Twist1 and increased metastasis in human gastric cancers (20) .
Discussion
Our study has provided convincing evidence that PAQR3 is actively involved in the degradation of Twist1, a critical transcription factor required for the initiation of EMT and metastasis of tumor cells. PAQR3 overexpression reduced the protein level but not the mRNA level of Twist1. The protein stability of Twist was enhanced by PAQR3 knockdown and lessened by PAQR3 overexpression. Ubiquitination of Twist1 was robustly elevated by PAQR3 overexpression. We also identified that PAQR3 formed a complex with Twist1 and BTRC ( Figure 4F ). PAQR3 could interact with both Twist1 and BTRC, whereas the interaction between Twist1 and BTRC was enhanced by PAQR3. Within the PAQR3/Twist1/BTRC complex, BTRC mediates ubiquitination of Twist1 due to its E3 ubiquitin ligase activity. Consequently, BTRC was required for PAQR3-indiced degradation of Twist1. Such idea is supported by the finding that Twist1 can be mobilized from the nucleus to proteasome-containing structures in the cytoplasm upon coexpression of PAQR3 and BTRC. Although both PAQR3 and BTRC are indispensable for Twist1 degradation, the functions of BTRC and PAQR3 are different. PAQR3 appears to mainly facilitate the formation of the degradation complex, whereas BTRC acts as an E3 ubiquitin ligase component of the complex. We also found that the Twist1 box domain of the Twist1 A and B) BTRC is required for the inhibitory effect of PAQR3 on migration and EMT of AGS cells. AGS cells stably expressing PAQR3 (PAQR3-OV) with or without a BTRC-specific shRNA (BTRC-KD) were used in a transwell assay to measure the cell migration rate (A). Quantitation of the data (means ± SD) is shown in the right panel with *** for P < 0.001 between the indicated groups. The cell lysate of these AGS cells was subjected to immunoblotting to detect endogenous E-cadherin, N-cadherin, Twist1, BTRC, PAQR3 and β-action. (C and D) Twist1 is required for the inhibitory effects of PAQR3 on migration and EMT of AGS cells. AGS cells stably expressing a PAQR3-specific shRNA (PAQR3-KD) with or without a Twist1-specific shRNA (Twist1-KD) were used in a transwell assay to measure the cell migration rate (C). The cell lysate of these cells was used in immunoblotting with the antibodies as indicated (D). (E and F) Knockdown of PAQR3 promotes metastasis of AGS cells in vivo and such activity requires Twist1. AGS cells used in (C) were used in an in vivo metastasis assay in nude mice. Invasion of the AGS cells was measured by in vivo detection of luciferase activity (E). Representative hematoxylin and eosin staining of the lungs of the mice at 6 weeks after the tail-vein injection is shown in (F). The arrows indicate the metastasized tumor nodule in the lung.
protein was required for the interaction of Twist1 with both PAQR3 and BTRC, with such domain being indispensable for PAQR3medicated degradation of Twist1. Finally, we found that both BTRC and Twist1 were required for the inhibitory effects of PAQR3 on migration and EMT phenotype of gastric cancers cells. Most importantly, Twist1 was crucial for the inhibitory effect of PAQR3 on metastasis of gastric cancer cells in vivo.
Twist1, as a member of bHLH family, is a conserved transcription factor that plays a critical role in regulating EMT during cancer metastasis (8, 33, 34) . Therefore, it is of great importance to comprehend the regulation of Twist1 in order to uncover the molecular insights of EMT and tumor metastasis. It was previously discovered that Twist1 could be regulated by a few factors. For example, HIF-1α could bind Twits promoter and directly regulates the transcription of Twist1, and such function is implicated in metastasis of lung cancers (9) . It also reported that the stability of Twist1 is affected through an interaction with p62 (35) . Our study has demonstrated that PAQR3 functions as a new player that regulates Twist1 at the post-translational level. Although we cannot rule out the possibility that other EMT signature proteins may partially compensate the functions of Twist1, our results clearly indicate that the regulatory effect of PAQR3 on Twist1 is closely associated with the alterations of EMT and metastasis of gastric cancer cells.
The discovery made in this study has provided a mechanistic explanation to the clinical findings. PAQR3 is robustly downregulated in human gastric cancers (20) . Downregulation of PAQR3 is significantly associated with distal metastasis and poor prognosis of the gastric cancer patients (20) . In patients with gastric cancers, downregulation of PAQR3 is closely associated with enhancement of EMT features of the gastric cancer represented such as an increase in the expression of Twist1 in the tumor tissues (20) . Consistent with our findings that PAQR3 forms a complex with Twist1 and BTRC, we found that both Twist1 and BTRC are required for the inhibitory effects of PAQR3 on migration and EMT phenotype of gastric cancer AGS cells. Furthermore, the enhanced metastasis of gastric cancer cells upon PAQR3 knockdown was completely abrogated by Twist1 knockdown. Therefore, in clinical settings, the EMT-promoting effect of PAQR3 downregulation in the tumor cells could be largely mediated by Twist1. If this were the case, a strategy to reduce the expression or activity of Twist1 could stand out as a promising therapy to curb metastasis of the tumors in the context of PAQR3 downregulation. Interestingly, targeting Twist1 has been recently proposed as a promising direction in cancer therapies (36) . Such strategy is especially enticing as PAQR3 downregulation has been frequently observed in many types of human cancers such as colorectal cancers (37) , gastric cancers (20) , hepatocellular carcinoma (38, 39) , bladder cancers (40) , osteosarcoma (41) and human breast cancers (42) .
